A Phase II trial of BXQ-350 in patients with Glioblastoma Multiforme (GBM)
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2019
Price : $35 *
At a glance
- Drugs Saposin C (Primary)
- Indications Glioblastoma; Glioma; Solid tumours
- Focus Therapeutic Use
- Sponsors Bexion Pharmaceuticals
- 30 Apr 2019 According to a Bexion Pharmaceuticals, proceeds from increase in series B funding will support this trial as well as two other studies.
- 30 Apr 2019 According to a Bexion Pharmaceuticals, this trial is expected to begin later this year.
- 30 Nov 2017 New trial record